Federica Nuti (1), Daniela Pugliese (2), Alessandro Armuzzi (2)
1U.O.C. di Gastroenterologia ed epatologia pediatrica, Policlinico Umberto I, Sapienza Università di Roma2IBD unit, complesso Integrato Columbus, Università Cattolica del Sacro Cuore di Roma
Inflammatory bowel diseases (iBd) including crohn’s disease (cd), ulcerative colitis and iBd undefined, present a chronic relapsing course causing heavy morbidity and impairment of quality of life. recently, therapeutic aims of iBd have moved from symptomatic control to the achievement of mucosal healing and deep remission. This has been possible with the advent of disease-modifying drugs, able to interrupt the inflammatory cascade underlying iBd, such as the biological agents. The latter are usually administered in subjects refractory to conventional therapies. However, their use in the initial phases of the disease could shutdown deeply the inflammatory process.